Immuno-psychiatry: an agenda for clinical practice and innovative research

BMC Medicine

Opinion

Michael Berk¹  David Kupfer²  Ryad Tamouza³  Laurent Groc⁴  Marion Leboyer⁵  Robert H. Yolken⁶ 

[1] Deakin University, IMPACT Strategic Research Centre (Barwon Health), School of Medicine, Geelong, VIC, Australia;The Florey Institute of Neuroscience and Mental Health, Orygen, National Centre of Excellence for Youth Mental Health, Parkville, VIC, Australia;Department of Psychiatry, University of Melbourne, Royal Melbourne Hospital, Parkville, VIC, Australia;Departments of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA;Fondation FondaMental, Creteil, France;INSERM, U1160, Hôpital Saint Louis, F75010, Paris, France;Laboratoire Jean Dausset, LabexTransplantex, Hôpital Saint Louis, F75010, Paris, France;Fondation FondaMental, Creteil, France;University of Bordeaux, UMR 5297, 33000, Bordeaux, France;Interdisciplinary Institute for Neuroscience, CNRS UMR 5297, 33077, Bordeaux, France;Psychiatry Department, University Paris-Est-Créteil, Mondor hospital, AP-HP, DHU PePSY, Translational Psychiatry laboratory, INSERM U955, Paris, France;Fondation FondaMental, Creteil, France;University of Bordeaux, UMR 5297, 33000, Bordeaux, France;Stanley Division of Developmental Neurovirology, The Johns Hopkins University School of Medicine, Baltimore, USA;

关键词: Personalised psychiatry;    Immune inflammation;    Biomarkers;    Biological pathways;    Translational research;   

DOI  :  10.1186/s12916-016-0712-5

 received in 2016-08-06, accepted in 2016-10-04,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundThe diagnostic scheme for psychiatric disorders is currently based purely on descriptive nomenclature given that biomarkers subtypes and clearly defined causal mechanisms are lacking for the vast majority of disorders. The emerging field of “immuno-psychiatry” has the potential to widen the exploration of a mechanism-based nosology, possibly leading to the discovery of more effective personalised treatment strategies.DiscussionDisturbances in immuno-inflammatory and related systems have been implicated in the aetiology, pathophysiology, phenomenology and comorbidity of several psychiatric disorders, including major mood disorders and schizophrenia. A fundamental challenge in their clinical management is to identify bio-signatures that might indicate risk, state, trait, prognosis or theragnosis. Here, we provide the rationale for a clinical and research agenda to refine future clinical practice and conceptual views, and to delineate pathways toward innovative treatment discovery.ConclusionThe development of bio-signatures will allow clinicians to tailor interventions to the abovementioned biomarker subtypes – a major translational goal for research in this field.

【 授权许可】

CC BY   
© The Author(s). 2016